Alivus Life Sciences (NSE:ALIVUS) Cash-to-Debt : N/A (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Alivus Life Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Alivus Life Sciences's cash to debt ratio for the quarter that ended in Dec. 2024 was N/A.

The historical rank and industry rank for Alivus Life Sciences's Cash-to-Debt or its related term are showing as below:

NSE:ALIVUS' s Cash-to-Debt Range Over the Past 10 Years
Min: 14.66 Med: 86.96 Max: No Debt
Current: 33.19

During the past 6 years, Alivus Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 14.66. And the median was 86.96.

NSE:ALIVUS's Cash-to-Debt is ranked better than
82.96% of 1015 companies
in the Drug Manufacturers industry
Industry Median: 1.03 vs NSE:ALIVUS: 33.19

Alivus Life Sciences Cash-to-Debt Historical Data

The historical data trend for Alivus Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Alivus Life Sciences Cash-to-Debt Chart

Alivus Life Sciences Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

1,465.14

No Debt

179.37

14.66

17.58

Alivus Life Sciences Quarterly Data
	Mar19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															N/A	17.58	N/A	33.19	N/A

Competitive Comparison of Alivus Life Sciences's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alivus Life Sciences's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Alivus Life Sciences's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

Alivus Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Alivus Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3014.14	/	(23.87	+	147.61)
	=	17.58

Alivus Life Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Alivus Life Sciences (NSE:ALIVUS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Alivus Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Alivus Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Alivus Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alivus Life Sciences Ltd (NSE:ALIVUS) » Definitions » Cash-to-Debt

Traded in Other Exchanges

543322:India

Address

470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099

Website

https://www.alivus.com

Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Alivus Life Sciences Headlines

No Headlines